Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
In the first three quarters of 2023, Denmark’s expenditure on the purchase of hospital medicine rose by 2.5% to almost 6.6 billion Danish kroner ($974.5 million). 26 December 2023
Pharmaceutical
US drugmaker Cidara Therapeutics’ shares advanced 12.5% to $0.83 on Friday, after it announced that Rezzayo (rezafungin acetate) has been approved in the European Union (EU) for the treatment of invasive candidiasis in adults. 23 December 2023
Pharmaceutical
In support of US President Biden’s Unity Agenda efforts to beat the overdose epidemic, the US Department of Health and Human Services (HHS) and the General Services Administration (GSA) announced new guidance. 23 December 2023
Pharmaceutical
USA-based Fauna Bio today announced a multi-year agreement with US pharma major Eli Lilly to apply Fauna's Convergence artificial intelligence (AI) platform to support pre-clinical drug discovery efforts in obesity. 22 December 2023
Pharmaceutical
The US Food and Drug Administration has approved AstraZeneca and Ionis Pharmaceuticals’ Wainua (eplontersen). 22 December 2023
Pharmaceutical
Suzhou, China-based cancer company CStone Pharmaceuticals has inked a deal with French drugmaker Servier to sell certain rights to Tibsovo (ivosidenib). 21 December 2023
Pharmaceutical
For a second time, the US Food and Drug Administration has rejected a submission from Merck & Co for approval to market a chronic cough medication. 21 December 2023
Pharmaceutical
India’s JB Chemicals & Pharmaceuticals saw its shares edge up 2% to 1,488.60 rupees, after it revealed it has acquired around 15 ophthalmology drugs from the Swiss pharma giant Novartis for rupees 964 crore or $116 million. 21 December 2023
Pharmaceutical
Tonix Pharmaceuticals Holding Corp has announced highly statistically significant and clinically meaningful topline results in a second positive Phase III trial of TNX-102 SL for the management of fibromyalgia. 21 December 2023
Pharmaceutical
Japanese drugmaker Shionogi has launched of siderophore cephalosporin antibiotic Fetroja (cefiderocol) intravenous infusion 1g vial in Japan. 21 December 2023
Pharmaceutical
As The World Health Organization (WHO) draws to a close COVAX, its pioneering global effort to distribute coronavirus vaccines, the agency said a new strain of the virus, JN.1, would be classed as a "variant of interest." 20 December 2023
Pharmaceutical
A feature analyzing recent pharma activity in the hepatology field and why NASH remains unchartered territory. 20 December 2023
Pharmaceutical
The rare disease unit of Italian drugmaker Chiesi has secured US approval for Filsuvez (birch triterpenes), a new treatment for people with junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB). 20 December 2023
Pharmaceutical
The contraceptives market across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, UK and Japan) is forecast to slightly increase at a compound annual growth rate (CAGR) of 0.5% from $7.8 billion in 2022 to $8.2 billion in 2032. 20 December 2023
Pharmaceutical
Foreign contract research companies (CROs) are suspending participating in clinical trials in Russia after the exodus of global drugmakers from the clinical research market in the country earlier this year, reports The Pharma Letter’s local correspondent. 20 December 2023
Pharmaceutical
Midsize Japanese drugmaker Otsuka Pharmaceuticals has entered into a licensing agreement with Ionis Pharmaceuticals related to its candidate donidalorsen. 19 December 2023
Pharmaceutical
Hoping to capitalize on a tsunami of interest in GLP-1 agonists for weight loss, Structure Therapeutics has now published Phase IIa data for its oral candidate, but investors are not happy. 19 December 2023
Pharmaceutical
In a new move within the pharmaceutical industry, French pharma major Sanofi has entered into a $140 million deal with Aqemia, a French pharmaceutical technology company. 19 December 2023
Pharmaceutical
Rain Oncology is to be acquired by Pathos AI for $1.16 per share, a 17% premium on the former firm’s share price. 18 December 2023
Pharmaceutical
Vicore Pharma, a Swedish pharma company seeking to unlock the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), has announced that Bertil Lindmark will join as chief medical officer. 18 December 2023
All news
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
Pharmaceutical
Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space.
How has the company achieved this — on the R&D and patient access side — and what is the company doing to help the remaining patients? Vertex’s Andrew Wilfin, Senior Country Medical Director, UK and Ireland, took part in a Q&A with The Pharma Letter to reveal all. 7 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial intelligence (AI) intended to support a regulatory decision about a drug or biological product’s safety, effectiveness or quality. 7 January 2025
Pharmaceutical
Sentynl Therapeutics, wholly owned by Zydus Lifesciences, has announced that the US Food and Drug Administration has accepted its New Drug Application for CUTX-101, a potential first treatment for Menkes disease. The application has been granted priority review, with a target action date set for June 30, 2025. 7 January 2025
Pharmaceutical
rug Administration (FDA) approved an update to the US Prescribing Information (USPI) for Pyrukynd (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency, Agios Pharmaceutical revealed in a Security and Exchange Commission (SEC) notice. 7 January 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze